Levofloxacin Hikma Farmacêutica (Portugal) (Levofloxacin)

Levofloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes that control DNA supercoiling and separation during replication. Inhibiting these enzymes prevents bacterial DNA synthesis and transcription, leading to rapid bactericidal activity against a wide range of Gram‑positive and Gram‑negative organisms.

The specific dose and duration of levofloxacin therapy are determined by the prescribing clinician based on the infection type, severity, patient weight, renal function, and local resistance patterns. Healthcare professionals should follow the latest clinical guidelines and product labeling when selecting a regimen.

Levofloxacin is classified as Pregnancy Category C, meaning it should be used only if the potential benefit justifies the potential risk to the fetus. It is excreted in breast milk, so breastfeeding mothers should discuss risks and alternatives with their healthcare provider before use.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed), and import documentation.

Levofloxacin is the L‑isomer of ofloxacin and offers higher potency with once‑daily dosing for many infections. Compared with older fluoroquinolones, it has a broader spectrum against Gram‑negative organisms and better lung penetration, but it shares class‑related safety concerns such as tendon toxicity and QT prolongation.

Levofloxacin injectable solution should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect from light, and avoid freezing or shaking the product, as temperature excursions can affect stability and potency.

The product is supplied as an injectable solution for intravenous infusion. Administration is performed by a qualified healthcare professional, typically over a period of 30‑60 minutes, using aseptic technique and appropriate infusion equipment as described in the product’s prescribing information.

Serious risks include tendon rupture (especially Achilles), QT interval prolongation leading to arrhythmias, severe hypersensitivity reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, and rare hepatic or neurological toxicity. Patients should be monitored closely for these events, particularly if risk factors are present.

Levofloxacin is contraindicated in patients with a known hypersensitivity to levofloxacin, other fluoroquinolones, or any component of the formulation. It should also be avoided in individuals with a history of tendon disorders related to fluoroquinolone use, uncontrolled epilepsy, or those receiving concomitant medications that significantly prolong the QT interval.